Summary of Study ST002737
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001702. The data can be accessed directly via it's Project DOI: 10.21228/M8Q42J This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST002737 |
| Study Title | 2’-fucosyllactose prevents colitis |
| Study Type | untargeted metabolomics analysis |
| Study Summary | Human milk-derived 2’-fucosyllactose (2’-FL) consumption is associated with health benefits in infancy that extend into adulthood. However, the exact biological functions of 2’-FL and corresponding mechanisms of action remain largely unknown. Here, we investigated the impact of 2’-FL on gut microbial metabolism for the prevention of colitis in adulthood. The gut microbiota from adult mice treated with 2’-FL showed an increase in abundance of several health-associated genera, including Bifidobacterium, and exhibited preventive effects on colitis. Microbial metabolic analysis demonstrated that 26 pathways that are significantly different between non-inflammatory bowel disease individuals and patients with ulcerative colitis (UC) are significantly regulated by 2’-FL in mice, indicating that 2’-FL has the potential to directly regulate dysregulated microbial metabolism in UC. Exploratory metabolomics of Bifidobacterium infantis identified novel secreted metabolites significantly enriched by 2’-FL consumption, including pantothenol. Remarkably, pantothenate significantly protects mucosal barrier and mitigates colitis in adult mice. Thus 2’-FL-modulated gut microbial metabolism may contribute to the prevention of intestinal inflammation in adulthood. |
| Institute | Vanderbilt University |
| Department | Chemistry |
| Laboratory | Center for Innovative Technology |
| Last Name | CODREANU |
| First Name | SIMONA |
| Address | 1234 STEVENSON CENTER LANE |
| SIMONA.CODREANU@VANDERBILT.EDU | |
| Phone | 6158758422 |
| Submit Date | 2023-06-15 |
| Num Groups | 2 |
| Total Subjects | 10 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | raw(Thermo) |
| Analysis Type Detail | LC-MS |
| Release Date | 2023-12-18 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Combined analysis:
| Analysis ID | AN004439 |
|---|---|
| Analysis type | MS |
| Chromatography type | Reversed phase |
| Chromatography system | Vanquish UHPLC binary system |
| Column | Thermo Hypersil Gold (100 x 2.1mm, 1.9um) |
| MS Type | ESI |
| MS instrument type | Orbitrap |
| MS instrument name | Thermo Q Exactive HF hybrid Orbitrap |
| Ion Mode | POSITIVE |
| Units | time_m/z |
Chromatography:
| Chromatography ID: | CH003335 |
| Chromatography Summary: | For the RPLC analysis metabolite extracts (5μL injection volume) were separated on a Hypersil Gold, 1.9 µm, 2.1mm x 100 mm column (Thermo Fisher) held at 40°C. Liquid chromatography was performed at a 250μL min-1 using solvent A (0.1% formic acid (FA) in water) and solvent B (0.1% FA in acetonitrile:water 80:20) over a 30 min gradient. Mass spectrometry analyses were performed in positive ion mode with the parameters as previously published except for the following changes. First, tandem mass spectra were acquired using a data dependent scanning mode in which one full MS scan (m/z 70-1050) was followed by 2 or 10 MS/MS scans. MS/MS scans are acquired in profile mode using an isolation width of 1.3 m/z, stepped collision energy (NCE 20, 40), and a dynamic exclusion of 6 s. |
| Instrument Name: | Vanquish UHPLC binary system |
| Column Name: | Thermo Hypersil Gold (100 x 2.1mm, 1.9um) |
| Column Temperature: | 40 |
| Flow Gradient: | 30 min |
| Flow Rate: | 0.25 mL/min |
| Solvent A: | 100% water, 0.1% Formic Acid |
| Solvent B: | 80:20 acetonitrile:water, 0.1% Formic Acid |
| Chromatography Type: | Reversed phase |
